Published in Cancer Weekly, November 1st, 2005
Quidel has acquired the immunochemical fecal occult blood test (iFOBT) from Alfa Scientific Designs, Inc. of Poway, California. This U.S. Food and Drug Administration (FDA) cleared and CLIA-waived test (which validates clinical efficacy and ease of use) will be marketed to healthcare professionals as the QuickVue iFOB test.
The immunochemical fecal occult blood test category represents a large market opportunity for Quidel as over 50 million fecal occult blood tests are sold...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.